Precision Medicine Is Becoming an Operations Business
The science is hard — the plumbing may be harder!
Precision medicine has always sounded beautifully simple: the right treatment, for the right patient, at the right time. In practice, it is becoming something much more complicated, ... and strategically much more interesting. The next bottleneck is turning complex biology into repeatable infrastructure.
Cell and gene therapy is the clearest example. It may be the purest expression of precision medicine: in some cases, the treatment is not just selected for the patient; it is made for the patient. Powerful? Absolutely. Operationally elegant? Not exactly. This is bespoke tailoring, except the suit is alive, temperature-sensitive, federally regulated, and has to be shipped back before anyone loses their nerve!
Autologous genetically modified cell therapy manufacturing can cost roughly $150K-$250K per patient, over a 2-4 week cycle, with meaningful cost layers across labor, documentation, raw materials, QA/QC, and CDMO profit. That is the strategic point: the therapy may be biological, but the constraint is increasingly industrial.
This is why tools and diagnostics are not supporting actors in precision medicine. They are the operating system.
The important companies will be the ones with the best therapeutic payloads and the ones that make the payload manufacturable, measurable, releasable, shippable, reimbursable, and clinically usable. Not glamorous, but neither is plumbing until it fails!
The same pattern shows up across modalities. In GLP-1s, the biggest tools opportunity is not exotic bioprocessing; it is fill/finish and packaging. We estimate ~$10B global TAM for fill/finish and $10B for packaging,... and ~1% of these figures for bioprocessing raw materials for current commercial GLP-1s. In oligonucleotides, the market may split between solid-phase synthesis for smaller rare disease volumes and enzymatic manufacturing for higher-volume common disease indications.
Different modality, same lesson: precision medicine does not scale on biology alone.
The industry loves to talk about breakthroughs. Fair enough. Breakthroughs are exciting. But the next era will be won by companies that can industrialize breakthroughs without killing the magic (or the margin)!
That means raw materials, release testing, automation, chain-of-custody, cold chain, companion diagnostics, biomarkers, reimbursement models, and clinical workflows all matter. A therapy that works beautifully in a trial but cannot be manufactured, shipped, paid for, or delivered at scale is not a revolution. It is a very expensive science project with a press release.
So this field note is this: precision medicine is moving from discovery to deployment. The first wave was about identifying the right patient. The next wave is about building the system that can reliably deliver the right intervention. Therapeutics may get the headlines — they are the rock stars. But tools, diagnostics, and manufacturing infrastructure are the sound engineers and tour managers. Without them, the show does not happen. And in healthcare, unlike Coachella, "the vibes were good" is not an acceptable release criterion.
The companies that matter most over the next decade may be the ones that make precision medicine boringly repeatable. In this field, that may be the highest compliment!